Antigenics Reports First Quarter 2010 Financial Results
Antigenics Inc. (NASDAQ: AGEN) reported today its results for the quarter ended March 31, 2010. The company reported a net loss attributable to common stockholders of $9.0 million, or $0.10 per share, basic and diluted, for the first quarter of 2010, compared with a net loss attributable to common stockholders in the first quarter of 2009 of $9.7 million, or $0.14 per share, basic and diluted. The company’s net cash burn (cash used in operating activities plus capital expenditures and dividend payments) for the first quarter of 2010 and 2009 respectively was $6.1 million and $9.8 million. The 2010 net cash burn figure primarily reflects the company’s efforts to support Oncophage as well as cost containment. Cash, cash equivalents and short-term investments amounted to $23.9 million as of March 31, 2010.
Conference Call Information
Antigenics executives will host a conference call at 11:00 a.m. Eastern Time today. To access the live call, dial 877.762.5772 (domestic) or 706.643.6986 (international); the access code is 69675455. The call will also be webcast and will be accessible from the company’s website at www.antigenics.com/webcast/. A replay will be available approximately two hours after the call through midnight Eastern Time on October 29, 2010. The replay number is 800.642.1687 (domestic) or 706.645.9291 (international), and the access code is 69675455. The replay will also be available on the company’s website approximately two hours after the live call.About Antigenics Antigenics is a biotechnology company working to develop treatments for cancers and infectious diseases. For more information, please visit www.antigenics.com. This earnings release contains forward-looking statements, including statements regarding development, regulatory and commercialization efforts, clinical trial activities, data, results and timelines of the company and its licensees and collaborators. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, decisions by regulatory authorities, physicians patients, and our licensees and collaborators; the possibility that clinical trial results will not be as favorable; the inability to secure local distributors, service providers, and payment mechanisms in Russia; the ability to raise capital and finance future activities; Antigenics’ dependence on its collaborative partners to successfully develop and commercialize products; and the factors described under the Risk Factors section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission for the period ended December 31, 2009. Antigenics cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this document, and Antigenics undertakes no obligation to update or revise the statements. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Antigenics’ business is subject to substantial risks and uncertainties, including those identified above. When evaluating Antigenics’ business and securities, investors should give careful consideration to these risks and uncertainties.
|Summary Consolidated Financial Information|
|Condensed Consolidated Statements of Operations Data|
|(in thousands, except per share data)|
|Three months ended March 31,|
|Research and development||4,631||4,905|
|General and administrative||3,566||3,904|
|Other expense, net||(1,550||)||(1,288||)|
Dividends on Series A convertible preferredstock
|Net loss attributable to common stockholders||$||(9,009||)||$||(9,674||)|
|Per common share data, basic and diluted:|
|Net loss attributable to common stockholders||$||(0.10||)||$||(0.14||)|
Weighted average number of common sharesoutstanding, basic and diluted
|Condensed Consolidated Balance Sheet Data|
|March 31, 2010||December 31, 2009|
|Cash, cash equivalents and short-term investments||$||23,937||$||30,065|
|Total stockholders' deficit||(24,408||)||(16,975||)|
Check Out Our Best Services for Investors
Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.